Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third Rock Launches Ember Therapeutics With Focus On Obesity And Type 2 Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

The sole investor in a $34 million Series A financing, Third Rock hopes Ember can be a pioneer in development of obesity drugs that augment brown fat levels.

You may also be interested in...



Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators

Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.

The A-List: The Trend-Shaping Series A Financings Of 2011

The capital drought that hit life science companies the past three years worked its way upstream in 2011, as several venture firms said they wouldn’t either continue in the life sciences or raise new funds. But our annual tally of life science Series A rounds presents a surprising twist: Series A rounds are up, not in blockbuster numbers by any stretch, but the downward trend of the recession years has finally been reversed. Among the year's nearly 100 Series A rounds we found plenty of oncology and peripheral vascular disease start-ups, as well as big bets on rare disease, along with some considerable nods to emerging markets.

Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million

The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel